Immatics

What started in 2000 as a small spin-out from H.G. Rammensee’s laboratory at the University of Tübingen, Germany, Immatics has emerged as a leader in the field of cancer immunotherapy. By combining state-of-the-art technology with deep expertise in tumor biology, Immatics aims to revolutionize the treatment landscape for cancer patients. The company focuses on identifying true targets that are presented on tumor tissues but not on healthy cells, thus laying the groundwork for the development of precise and effective therapies.

Immatics offers a robust pipeline that includes Adoptive Cell Therapies and TCR Bispecific substances. The heart of Immatics' innovation lies in its proprietary technologies like XPRESIDENT® and XCEPTOR®, which enable the discovery, development, and validation of T cell receptors (TCRs) that can specifically engage with cancer cells. Through these tailored approaches, Immatics aspires to deliver the power of T cells to cancer patients, unleashing a new wave of therapeutic solutions targeting solid tumors.

The company has partnered with leading global pharmaceutical firms, enhancing its capabilities and accelerating the path from laboratory discovery to patient treatment. As it continues to develop its promising therapies, Immatics remains deeply committed to the fight against cancer, with the singular goal of improving patient outcomes and making a tangible impact in the lives of those affected by this devastating disease.